Browsing by Author "Demirci, Umut"
Now showing items 1-16 of 16
-
Comparison of response and survival of first-line crizotinib therapy according to EML-4 ALK fusion variants in advanced non-small cell lung cancer patients: A Turkish Oncology Group study
Tatlı, Ali Murat; Yumuk, Perran Fulden; Öz, Büge; Bilici, Ahmet; Gürsoy, Pınar; Göker, Erdem; Sezer, Ahmet; Özet, Ahmet; Demirci, Umut; Bozkurtlar, Emine; Özbudak, İrem Hicran; Nart, Deniz; Canpolat, Tuğba; Akyürek, Nalan; Kılıçkap, Saadettin (Zerbinis Publications, 2021)Purpose: In the literature there are conflicting data about the treatment efficacy of anaplastic lymphoma kinase (ALK) translocation positive non-small cell lung cancer (NSCLC) patients according to ALK fusion variants. ... -
Crizotinib efficacy in alk-positive advanced stage non-small cell lung cancer patients: A real-world experience from Turkey
Kılıçkap, Sadettin; Öztürk, Akın; Karadurmuş, Nuri; Korkmaz, Taner; Yumuk, Perran Fulden; Çiçin, İrfan; Paydaş, Semra; Çılbır, Ebru; Sakalar, Teoman; Uysal, Mükremin; Üskent, Necdet; Demir, Nurcan; Sakin, Ayşegül; Turhal, Nazım Serdar; Keskin, Serhat; Tural, Deniz; Eralp, Yeşim; Buğdaycı Başal, Fatma; Yaşar, Hatime Arzu; Sendur, Mehmet Ali Nahit; Demirci, Umut; Çubukçu, Erdem; Karaağaç, Mustafa; Karaca, Saziye; Tatlı, Ali Murat; Yetişyiğit, Tarkan; Urvay, Semiha; Gürsoy, Pınar; Oyan Uluç, Başak; Turna, Zeynep Hande; Küçüköner, Mehmet; Ölmez, Ömer Fatih; Çabuk, Devrim; Şeker, Mesut; Ünal, Olçun Umut; Meydan, Nezih; Okutur, Sadi Kerem; Tunalı, Duygu (Elsevier Science Inc, 2018)Background: Increasing evidence leads to a ratiocination that genetic heterogeneity of the lung adenocarcinoma patients with sensitive EGFR mutations may impact clinical responses and outcomes to EGFR-TKIs. Method: We ... -
The effect of primary surgery in patients with de novo stage IV breast cancer with bone metastasis only (Protocol BOMET MF 14-01): A multi-center, prospective registry study
Soran, Atilla; Doğan, Lütfi; Işık, Arda; Özbaş, Serdar; Can Trabulus, Didem; Demirci, Umut; Karanlık, Hasan; Soyder, Aykut; Dağ, Ahmet; Bilici, Ahmet; Doğan, Mutlu; Köksal, Hande; Şendur, Mehmet Ali Nahit; Gülçelik, Mehmet Ali; Maralcan, Göktürk; Cabıoğlu, Neslihan; Yeniay, Levent; Utkan, Zafer; Şimşek, Turgay; Karadurmuş, Nuri; Dağlar, Gül; Yıldız, Birol; Uras, Cihan; Tükenmez, Mustafa; Yıldırım, Ahmet; Kutun, Suat; Özaslan, Cihangir; Karaman, Niyazi; Akçay, Müfide Nuran; Toktaş, Osman; Sezgin, Efe (Springer, 2021)Background More evidence shows that primary surgery for de novo metastatic breast cancer (BC) prolongs overall survival (OS) in selected cases. The aim of this study was to evaluate the role of locoregional treatment (LRT) ... -
The effect of primary surgery in patients with stage IV breast cancer with bone metastasis only (protocol bomet MF14-01); a multi-center, registry study
Soran, Atilla; Doğan, Lütfi; Özbaş, Serdar; Işık, A.; Can Trablus, Didem; Demirci, Umut; Karanlık, Hasan; Soyder, Aykut; Dağ, Ahmet; Bilici, Abdullah Yasin; Ertaş Doğan, Mehtap; Köksal, Hilal; Şendur, Mehmet Ali Nahit; Gülçelik, Mehmet Ali; Maralcan, Göktürk; Cabıoğlu, Neslihan; Yeniay, Levent; Utkan, Zafer; Şimşek, Tuncay; Karadurmuş, Nun; Dağlar, Gülseren; Yıldız, Barış Doğu; Uras, Cihan; Tükenmez, Mustafa; Yıldırım, Ahmet Özgür; Kutun, Suat; Özaslan, Cihangir; Karaman, Niyazi; Akçay, Müfide Nuran; Toktaş, Osman; Sezgin, Efe Cumhur (Churchill Livingstone, 2021)... -
The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey
Kılıçkap, Saadettin; Ölmez, Ömer Fatih; Cicin, İrfan; Demirci, Umut; Alan, O.; Çabuk, Devrim; Sakalar, Teoman; Tatlı, Ali Murat; Buğdaycı, F. Başol; Eralp, Yeşim; Uysal, Mükremin; Demirkazik, Ahmet; Bilgin, Burak; Yıldız, Birol; Karaağaç, Mustafa; Okutur, Kerem; Sakin, Ayşegül (Oxford University Press, 2018)… -
Glass: Global lorlatinib for ALK(+) and ROS1(+) retrospective study: Real world data of 123 NSCLC patients
Peled, Nir; Gillis, Roni; Kılıçkap, Saadettin; Froesch, Patrizia; Orlov, Sergei; Filippova, Elena; Demirci, Umut; Christopoulos, Petros; Çiçin, İrfan; Buğdaycı Basal, Fatma; Yılmaz, Cengiz; Fedor, Moiseenko; Korkmaz, Taner; Paydaş, Semra; Gautschi, Oliver; Zırtıloğlu, Alişan; Eralp, Yeşim; Yeşil Çınkır, Havva; Sezer, Ahmet; Erman, Mustafa; Tural, Deniz; Turna, Hande; Mazieres, Julien; Dudnik, Elizabeth; Reguart, Noemi; Camidge, David Ross; Ng, Terry L.; Çay Şenler, Filiz; Beypınar, İsmail; Yazılıtaş, Doğan; Demirkazık, Ahmet; Karaoğlu, Aziz; Okutur, Kerem; Coşkun, Hasan Şenol; Şendur, Mehmet Ali Nahit; Işıkdoğan, Abdurrahman; Çabuk, Devrim; Yumuk, Perran Fulden; Yıldız, İbrahim; Kaplan, Mehmet Ali; Özyılkan, Özgür; Öztop, İlhan; Ölmez, Ömer Fatih; Aydın, Kübra; Aydıner, Adnan; Meydan, Nezih; Grinberg, Roxana Denisa; Roisman, Laila C. (Elsevier Science Inc, 2021)Introduction: Lorlatinib is a third-generation tyrosine-kinases inhibitor (TKI) targeting ALK/ROS1 fusions. The FDA has approved lorlatinib for TKI-pretreated ALK(+) NSCLC, while its approval for ROS1(+) is still pending. ... -
Glass: Global lorlatinib for ALK(+) and ROS1(+) retrospective study: Real world data of 123 NSCLC patients
Peled, Nir; Gillis, Roni; Kılıçkap, Saadettin; Froesch, Patrizia; Orlov, Sergei; Filippova, Elena; Demirci, Umut; Christopoulos, Petros; Çiçin, İrfan; Buğdaycı Basal, Fatma; Yılmaz, Cengiz; Fedor, Moiseenko; Korkmaz, Taner; Paydaş, Semra; Gautschi, Oliver; Zırtıloğlu, Alişan; Eralp, Yeşim; Yeşil Çınkır, Havva; Sezer, Ahmet; Erman, Mustafa; Tural, Deniz; Turna, Hande; Mazieres, Julien; Dudnik, Elizabeth; Reguart, Noemi; Camidge, David Ross; Ng, Terry L.; Çay Şenler, Filiz; Beypınar, İsmail; Yazılıtaş, Doğan; Demirkazık, Ahmet; Karaoğlu, Aziz; Okutur, Kerem; Coşkun, Hasan Şenol; Şendur, Mehmet Ali Nahit; Işıkdoğan, Abdurrahman; Çabuk, Devrim; Yumuk, Perran Fulden; Yıldız, İbrahim; Kaplan, Mehmet Ali; Özyılkan, Özgür; Öztop, İlhan; Ölmez, Ömer Fatih; Aydın, Kübra; Aydıner, Adnan; Meydan, Nezih; Grinberg, Roxana Denisa; Roisman, Laila C. (Elsevier Ireland Ltd, 2020)Lorlatinib is a third-generation tyrosine-kinases inhibitor (TKI) targeting ALK/ROS1 fusions. The FDA has approved lorlatinib for TKI-pretreated ALK(+) NSCLC, while its approval for ROS1( + ) is still pending. Here we ... -
Locoregional treatment improves survival in de novo bone-only metastatic breast cancer: Long-term results of the prospective, multi-institutional study - protocol BOMET MF14-01
Soran, Atilla; Doğan, Lütfi; Işık, Arda; Özbaş, Serdar; Can Trabulus, Didem; Demirci, Umut; Karanlık, Hasan; Soyder, Aykut; Dağ, Ahmet; Bilici, Ahmet; Doğan, Mutlu; Şendur, Mehmet Ali Nahit; Köksal, Hande; Gülçelik, Mehmet Ali; Cabıoğlu, Neslihan; Yeniay, Levent; Utkan, Zafer; Karadurmuş, Nuri; Dağlar, Gül; Şimşek, Turgay; Yıldız, Birol; Uras, Cihan; Tükenmez, Mustafa; Özaslan, Cihangir; Maralcan, Göktürk; Kutun, Suat; Karaman, Niyazi; Toktaş, Osman; Yıldırım, Ahmet Özgen; Akçay, Müfide Nuran; Özmen, Vahit; Sezgin, Efe (Springer, 2023)... -
Lorlatinib in ALK- or ROS1-positive non-small cell lung cancer patients: Experience from an early access program in Turkey
Kılıçkap, Saadettin; Demirci, Umut; Buğdaycı, Fatma; Tural, Deniz; Korkmaz, Taner; Paydaş, Semra; Yılmaz, Coşkun; Tuna, Hande; Sezer, Ahmet; Yeşil Çinkir, Havva; Erman, Münire; Eralp, Yeşim; Çabuk, Devrim; Işıkdoğan, Abdurrahman; Demirkazık, Ahmet; Karaoğlu, Aziz; Yazılıtaş, Doğan; Çay Şenler, Filiz; Yumuk, Perran Fulden; Coşkun, Hatice; Yıldız, İbrahim; Öztop, İlhan; Beypınar, İsmail; Aydın, Kübra; Kaplan, M.; Meydan, Nezih; Ölmez, Ömer Fatih; Seber, Samile; Arslan, Çağatay; Şendur, Mehmet Ali Nahit; Çiçin, İrfan (Elsevier Science, 2019)Background: Lorlatinib, a third generation ALK and ROS1 inhibitor, is indicated for the treatment of patients with ALK+ metastatic NSCLC whose disease has progressed on crizotinib and at least one second-generation ALK ... -
Merkel cell carcinoma in Turkey: A multicentric study
Yıldız, Fatih; Demirci, Umut; Küçükarda, Ahmet; Büyükşimşek, Mahmut; Sakalar, Teoman; Öztürk Topçu, Türkan; Aslan, Ferit; Tufan, Gülnihal; Aydın, Övgü; Turna, Hande; Akgül Babacan, Nalan; Başoğlu, Tugba; Kurt, Bediz; Yıldız, Birol; Eren, Tülay; Demiray, Atike Gökçen; Gümüşay, Özge; Arslan, Çağatay; Özdemir, Nuriye; Ürün, Yüksel; Baykara, Meltem; Turan, Nedim; Uysal, Mükremin; Bilici, Ahmet; Kavgacı, Halil; Çiçin, İrfan; Kılıçkap, Saadettin; Paydaş, Semra (Wolters Kluwer Medknow Publications, 2021)Background: Merkel cell carcinoma (MCC) is a rare but highly aggressive neuroendocrine carcinoma of the skin. In this study, we aimed to evaluate the clinicopathologic characteristics, treatment outcomes, and survival of ... -
Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors
Gümüş, Mahmut; Bilici, Ahmet; Odabaş, Hatice; Öven Ustaalioğlu, Bala Başak; Kandemir, Nurten; Demirci, Umut; Cihan, Şener; Bayoğlu, İbrahim Vedat; Öztürk, Türkan; Türkmen, Esma; Urakçı, Zürat; Şeker, Mehmet Metin; Günaydın, Yusuf; Selçukbiricik, Fatih; Turan, Nedim; Sevinç, Alper (Springer, 2017)Background Currently, it is accepted that risk assessment of clinical stage I (CS I) nonseminomatous germ cell tumors (NSGCT) patient is mainly dependent on the presence of lymphovascular invasion (LVI). Initial active ... -
Outcomes of surveillance VS. adjuvant chemotherapy for patients with STAGE IA and IB NON-seminomatous testicular germ-cell tumors
Bilici, Ahmet; Gümüş, Mahmut; Odabaş, Hatice; Kandemir, Nurten; Demirci, Umut; Cihan, Şener; Bayoğlu, İbrahim Vedat; Öven Ustaalıoğlu, Bala Başak; Öztürk, Türkan; Türkmen, Esma; Urakçı, Zuhat; Şeker, Mehmet Metin; Günaydın, Yusuf; Selçukbiricik, Fatih; Turan, Nedim; Sevinç, Alper (American Society of Clinical Oncology, 2016)... -
Pertuzumab, trastuzumab and taxane combination for visceral organ metastatic patients: Real life practice results
Esin, Ece; Çakmak Öksüzoğlu, Ömür Berna; Bilici, Ahmet; Çiçin, İrfan; Aksoy, Sercan; Alacacıoğlu, Ahmet; Kaplan, Mehmet Ali; Çabuk, Devrim; Sümbül, Ahmet Taner; Paydaş, Semra; Sakin, Ayşegül; Korkmaz, Tuba; Özdemir Yıldırım, Nuriye; Artaç, Mehmet; Harputluoğlu, Hakan; Yumuk, Perran Fulden; Atalay Başaran, Gül; Oyan Uluç, Başak; Demirci, Umut (Oxford University Press, 2018)... -
Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: Real-life practice outcomes
Esin, Ece; Çakmak Öksüzoǧlu, Berna; Bilici, Ahmet Erkan; Çiçin, İrfan; Köstek, Osman; Kaplan, Mehmet Ali; Aksoy, Sercan; Aktaş, Burak Yasin; Özdemir, Özlem; Alacacıoğlu, Ahmet; Çabuk, Devrim; Sümbül, Ahmet Taner; Sakin, Abdullah; Paydaş, Semra; Yetişir, Ersin; Er, Özlem; Korkmaz, Taner; Yıldırım, Nilgün; Şakalar, Teoman; Demir, Hacer; Artaç¸, Mehmet; Karaaǧaç, Mustafa; Harputluoǧlu, Hakan; Bilen, Ebru; Erdur, Erkan; Deǧirmencioǧlu, Serkan; Aliyev, Altay; Çil, Timuçin; Olgun, Polat; Başaran, Gül Atalay; Gümüşay, Özge; Demir, Atakan; Tanrıkulu, Eda; Yumuk, Perran Fulden; İmamoğlu, İnanç; Oyan, Başak; Çetin, Bülent Eren; Haksöyler, Veysel; Karadurmuş, Nuri; Ertürk, İsmail; Evrensel, Türkkan; Yılmaz, Hasan; Beypınar, İsmail; Koçer, Murat; Pilancı, Kezban Nur; Şeker, Mesut Metin; Ürün, Yüksel; Yıldırım, Nuriye O.; Eren, Tülay; Demirci, Umut (Springer, 2019)PurposeIn this study, we aimed to describe the real-life practice outcomes of pertuzumab-trastuzumab-taxane (PTT) combination in visceral organ metastatic, trastuzumab-naive breast cancer (BC) patients.MethodsThis study ... -
Prognostic factors for lymph node negative stage I and IIA non-small cell lung cancer: Multicenter experiences
Ustaalioğlu Öven, Başak Bala; Ünal, Olçun Ümit; Turan, Nedim; Bilici, Ahmet Erkan; Kaya, Serap; Eren, Tülay; Ulaş, Arife; İnal, Ali; Berk, Veli; Demirci, Umut; Alıcı, Süleyman; Bal, Öznur; Benekli, Mustafa; Gümüş, Mahmut (Asian Pacific Organization for Cancer Prevention, 2013)Surgery is the only curative treatment for operable non-small lung cancer (NSCLC) and the importance of adjuvant chemotherapy for stage IB patients is unclear. Herein, we evaluated prognostic factors for survival and factors ... -
Treatment preferences in stage IA and IB testicular seminoma: Multicenter study of anatolian society of medical oncology
Bilici, Ahmet; Öztürk, Türkan; Türkmen, Esma; Odabaş, Hatice; Cihan, Şener; Selçukbiricik, Fatih; Erdoğan, Bülent; Urakçı, Zuhat; Kandemir, Nurten; Bayoğu, İbrahim Vedat; Demirci, Umut; Ocak Duran, Ayşe; Şendur, Mehmet Ali; Yavuzer, Dilek; Harputluoğlu, Hakan; Kavgacı, Halil; Gümüş, Mahmut (Springer, 2015)Approximately 75 % of patients with testicular seminoma present with stage I disease, and the probability of long-term survival approaches 100 %. However, the standard adjuvant treatment for stage I seminoma patients remains ...
